Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”

NEW YORK and LONDON, April 27, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a statement that Edison Investment Research Ltd. has withdrawn its report issued yesterday titled “Akari’s Coversin matches Soliris in Phase II” (the “Edison Report”) because it contains material inaccuracies, including without limitation, with respect to Akari’s […]

Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets

NEW YORK and LONDON, April 24, 2017 -Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in 4Q2017 -Data from preclinical aHUS model demonstrates positive results -New preclinical data demonstrates positive response of Coversin’s combined C5 and LTB4 therapy in skin and eye models -Phase 2 programs […]

Akari Therapeutics to Present at the Jefferies Complement Symposium

NEW YORK and LONDON, April 3, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the Jefferies Complement Symposium on April 6, 2017, in Boston, Massachusetts. The company is scheduled to present at 2:10 PM ET. Click here to see full […]

Akari Therapeutics Announces FDA Fast Track Designation For Coversin

NEW YORK and LONDON, March 30th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for Coversin™ for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who have polymorphisms conferring eculizumab resistance. Coversin™ is a second-generation complement inhibitor […]

Akari Therapeutics Announces R&D Day on April 24, 2017

NEW YORK and LONDON, March 17th, 2017 — Presentation to Include New Coversin Phase II Data in PNH and Latest Data on Pipeline – Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. The event will […]